Bone Marrow Hypocellularity in Patients with End-Stage Kidney Disease
by
, ,
Chia-Chen Hsieh
1,2, 
Ming-Jen Chan
1,2,
Yi-Jiun Su
3,
Jen-Fen Fu
2,4,
I-Kuan Wang
5,6,
Chao-Yu Chen
1,2,
Cheng-Hao Weng
1,2,
Wen-Hung Huang
1,2,
Ching-Wei Hsu
1,2 and
Tzung-Hai Yen
1,2,* 1
Clinical Poison Center, Department of Nephrology, Chang Gung Memorial Hospital, Linkou 333, Taiwan
2
College of Medicine, Chang Gung University, Taoyuan 333, Taiwan
3
Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou 333, Taiwan
4
Department of Medical Research, Chang Gung Memorial Hospital, Linkou 333, Taiwan
5
Department of Nephrology, China Medical University Hospital, Taichung 404, Taiwan
6
College of Medicine, China Medical University, Taichung 406, Taiwan
*
Author to whom correspondence should be addressed.
Healthcare 2021, 9(11), 1452; https://doi.org/10.3390/healthcare9111452
Submission received: 4 September 2021
/
Revised: 12 October 2021
/
Accepted: 22 October 2021
/
Published: 27 October 2021
(This article belongs to the Special Issue Prevention and Management of Kidney Injury)
Abstract
:Background. Anemia and pancytopenia are not uncommon in patients with chronic kidney disease (CKD). Nevertheless, there is insufficient literature analyzing bone marrow pathology in patients with CKD or end-stage kidney disease (ESKD) receiving dialysis. Methods. This observational cohort study included 22 patients with ESKD and 23 patients with CKD that received bone marrow biopsy and aspiration at Chang Gung Memorial Hospital. Demographic, hematological, and biochemical data were collected at the time of bone marrow study for analysis. Results. Bone marrow aspiration demonstrated that patients with ESKD had a lower percentage of blasts than patients with CKD (0.52 ± 0.84 versus 1.06 ± 0.78 %, p = 0.033). Bone marrow biopsy revealed that the overall incidence of hypocellular bone marrow was 55.6%. Furthermore, patients with ESKD had higher proportion of hypocellular bone marrow than patients with CKD (72.7% versus 39.1%, p = 0.023). In a multivariate logistic regression model, it was revealed that ESKD status (odds ratio 9.43, 95% confidence interval 1.66–53.63, p = 0.011) and megakaryocyte count within bone marrow (odds ratio 0.48, 95% confidence interval 0.29–0.79, p = 0.004) were significant predictors for bone marrow hypocellularity. Conclusion. Bone marrow hypocellularity is common in patients with kidney dysfunction. Hypocellular marrow occurs more frequently in patients with ESKD than patients with CKD.
1. Introduction
Anemia and pancytopenia are not uncommon in chronic dialysis patients. Nevertheless, there is insufficient literature analyzing bone marrow pathology in patients with chronic kidney disease (CKD) or end-stage kidney disease (ESKD) receiving chronic dialysis (Table 1) [1,2,3,4,5,6]. As early as 1950, Callen et al. [6] studied 102 patients with nephritis, related diseases and hypertension, and found that 80% of patients with CKD suffered hypercellular bone marrow. On the other hand, Eschbach et al. [5] found hypocellular bone marrow in 53.3% of patients with CKD. However, Ho-Yen et al. [4] studied bone marrow biopsies of 15 patients with CKD compared with those of a control group matched for age and sex. Although the percentage of two groups was not mentioned, there was no significant difference in bone marrow cellularity. In patients with ESKD receiving chronic dialysis, Sikole et al. [3] reported that 60% of patients suffered hypocellular bone marrow. Finally, Weng et al. [2] also reported that hypocellular bone marrow was present in 51.3% of ESRD patients undergoing chronic dialysis.
Taiwan is an epidemic area of kidney disease. The motivation for this research was due to a significant, but as yet unsatisfactorily answered question that occurred in many CKD or ESKD patients receiving chronic dialysis at our hospital. Some of our patients suffered peripheral blood cytopenia, but other patients did not have cytopenia. Theoretically, blood cells are produced in the bone marrow. Thus, this brings up an important question of what the bone marrow pathology of the uremic patients is.
Hypocellular bone marrow with pancytopenia could be caused by aplastic anemia, inherited bone marrow failure syndromes, drugs, toxins, infections, nutritional disorders, or autoimmune disorders [7]. Therefore, the objective of this study was to analyze bone marrow changes in patients with CKD and/or ESKD receiving dialysis.
2. Materials and Methods
2.1. Patients
Between 2001 and 2020, a total of 22 patients with ESKD undergoing chronic dialysis (aged 17.0–80.0 years, 59.1% male) and 23 patients with CKD (aged 39.0–81.0 years, 39.1% male) received a bone marrow biopsy and aspiration at the Chang Gung Memorial Hospital, Linkou, Taiwan. Baseline demographic, hematological, and biochemical data including hemogram, kidney function, liver function, ferrokinetics, lipid and electrolyte profiles were obtained at the time of the bone marrow study for cross-sectional analysis.
2.2. Inclusion and Exclusion Citeria
All patients with ESKD or CKD who underwent bone marrow biopsy were recruited for this study. Patients who had diagnoses of hematological malignancies that affected the blood, bone marrow, and lymph nodes such as leukemia, multiple myeloma, amyloidosis, and myelodysplastic syndrome were excluded from analysis.
2.3. Definitions and ESKD and CKD
CKD was defined by the presence of kidney damage or estimated glomerular filtration rate (eGFR) of less than 60 mL/min per 1.73 m2 for more than 3 months [8]. CKD Stage 3 included patients with an eGFR of 30–59 mL/min/1.73 m2, and CKD Stage 4 patients have an eGFR of 15–29 mL/min/1.73 m2. CKD Stage 5 included patients with an eGFR of <15 mL/min/1.73 m2. ESKD was the last stage of CKD, and the term was used to indicate those patients who undergo chronic dialysis treatment.
2.4. Bone Marrow Aspiration and Biopsy Procedure
The hemostatic profile of the patients was checked before examination. The procedure was performed under local analgesia with lateral decubitus position. The usual site for bone marrow examination was the posterior iliac crest if the patient was mobile without bony lesion. Methods for the preparation, processing, and reporting of bone marrow aspirates and biopsy specimens were executed according to published guidelines [9].
2.5. Definition of Bone Marrow Cellularity
Bone marrow pathology report was the gold standard to evaluate bone marrow cellularity [10]. Hematopoietic stem cells and stromal cells (generally adipocytes) were contained in bone marrow, and marrow cellularity was defined as the volume ratio of hematopoietic cells and adipocytes. The range of normal cellularity in adult hematopoietic bone marrow was 30 to 70% that varied according to patient’s age. Hypercellular marrow was defined as cellularity of more than 70%, normocellular marrow as ratio 30 to 70%, and hypocellular marrow as under 30% bone marrow [9].
2.6. Laboratory
Laboratory analysis, including hemogram, kidney function, liver function, ferrokinetics, lipid and electrolyte profiles were measured by automated and standardized methods. The complete blood count with differential was quantified by automated cell counter, blood urea nitrogen, alanine aminotransferase and total cholesterol by enzymatic method, creatinine, albumin, triglyceride, iron and ferritin by colorimetric method, calcium, high and low density lipoprotein by spectrophotometric method, phosphate, sodium, and potassium by ion-selective electrode method, total iron binding capacity by nephelometry method, glycated hemoglobin by high performance liquid chromatography.
2.7. Statistical Analysis
Data were presented as mean ± standard deviation or number and percentage in parentheses. Student’s t-test was used for parametric variables and Chi-Square or Fisher’s exact test, for non-parametric variables. Univariate binary logistic regression analysis was conducted to analyze the potential risk factors for bone marrow hypocellularity. To control for confounding factors, multivariate binary logistic regression analysis was completed to analyze the significant risk factors on univariate analysis. A p value of less than 0.05 was designated as the significance level to reject the null hypothesis. Analyses were completed using IBM SPSS Statistics Version 20.0 (IBM Corp., New York, NY, USA).
3. Results
The indications for bone marrow examination were presented in Table 2. Unexplained anemia (88.9%) was the most common indication for bone marrow biopsy in both the ESKD (81.8%) and CKD (95.7%). There were also no significant differences in the indications for a biopsy between the ESKD and CKD (p = 0.146).
The mean age of patients underwent bone marrow examination was 57.0 ± 16.4 years with roughly equal sex distribution (48.9% male, Table 3). A large proportion of patients (91.1%) had hypertension. Diabetes mellitus (46.7%) was the major cause of renal dysfunction in the patients. Most patients (73.3%) were in Stage 5 of CKD. Furthermore, patients with ESKD were younger compared to patients with CKD (52.1 ± 18.6 versus 61.7 ± 12.6 years, p = 0.047).
As shown in Table 4, patients with ESKD had higher blood urea nitrogen (83.4 ± 30.2 versus 63.1 ± 29.5, p = 0.041), creatinine (11.4 ± 3.1 versus 4.1 ± 2.0 mg/dL, p < 0.001), calcium level (9.4 ± 1.3 versus 8.2 ± 0.8 mg/dL, p = 0.008), and lower estimated glomerular filtration rate (4.7 ± 1.5 versus 16.9 ± 12.9 cc/min, p < 0.001) compared to patients with CKD. Furthermore, patients with ESKD had lower hemoglobin (7.3 ± 1.3 versus 8.4 ± 1.6 g/dL, p = 0.017), hematocrit (21.9 ± 3.9 versus 25.0 ± 4.9 %, p = 0.025), and red blood cell count (2.4 ± 0.4 versus 2.8 ± 0.6 106/μL, p = 0.046) than patients with CKD.
The reports of bone marrow aspiration are presented in Table 5. Patients with ESKD had lower percentage of blasts than patients with CKD (0.5 ± 0.8 versus 1.1 ± 0.8 %, p = 0.033).
The reports of bone marrow biopsies are presented in Table 6. The percentage of hypocellular bone marrow was 55.6% (Table 6). Patients with ESKD had higher percentage of hypocellular bone marrow than patients with CKD (72.7% versus 39.1%, p = 0.023).
In a multivariate logistic regression model (Table 7), it was shown that ESKD status (odds ratio 9.43, 95% confidence interval 1.66–53.63, p = 0.011) and megakaryocyte counts within bone marrow (odds ratio 0.48, 95% confidence interval 0.29–0.79, p = 0.004) were significant predictors for bone marrow hypocellularity.
4. Discussion
Although abnormal hematological profiles are prevalent in patients with kidney dysfunction, limited literature has investigated bone marrow pathology in uremic populations. This is supposed to be the first study analyzing bone marrow pathology of patients with CKD and ESKD at the same time. Although bone marrow biopsy is crucial for identifying causes for peripheral blood cytopenia in patients with kidney dysfunction, the procedure is not routinely performed in clinical practice due to its invasive nature and potential risk [11]. Only a few studies with small sample sizes explored bone marrow pathology, and the results also varied widely (Table 1). Therefore, this analytical data is important as it confirmed that bone marrow hypocellularity was common (55.6%) in patients with kidney dysfunction. Furthermore, hypocellular marrow occurred more frequently in patients with ESKD compared with patients with CKD (72.7% versus 39.1%, p = 0.023).
There is no clear-cut explanation for bone marrow hypocellularity in patients with kidney dysfunction. Accumulation of uremic toxin may have deleterious effects on bone marrow cells [12]. Potential inhibition of erythropoiesis by uremic sera has been reported by an in vitro study [13]. Indoxyl sulfate, one of soluble uremic toxins accumulated during CKD, is known to impair erythropoiesis via a hypoxia-induced factor pathway [14]. In addition, indoxyl sulfate also induces eryptosis via extracellular calcium entry [15]. Indoxyl sulfate also cause erythrocyte death via organic anion transporter 2, nicotinamide adenine dinucleotide phosphate oxidase, and glutathione-independent mechanisms [16]. Such toxicity not only affects the mature erythrocyte, but also affects progenitor cells. Other uremic toxins may also interfere erythropoiesis. Polyamines have been demonstrated to reduce proliferation and maturation of erythroid precursor cells [17]. Acrolein, one of the oxidation products of polyamines, may also promote suicidal erythrocyte death via cell membrane scrambling and cell shrinkage [18]. Burst-forming unit-erythroid proliferation rate is reduced by uremic serum. However, such inhibition of proliferation attenuates if the uremia patient is treated with hemodiafiltration with endogenous reinfusion, a method known to have better removal of uremic toxin [19]. Nevertheless, toxic effects of uremic toxin on bone marrow are still poorly understood.
In this study, patients with ESKD suffered lower hemoglobin (p = 0.017), hematocrit (p = 0.025) and red blood cell count (p = 0.046) than patients with CKD. Anemia in patients with ESKD receiving chronic dialysis could be explained by chronic blood loss, decreased erythrocyte production, or increased erythrocyte destruction. The kidneys are the chief organs of erythropoietin production in adults, while in fetuses the liver is the primary organ of erythropoietin gene expression [20]. With advancing renal impairment, erythropoietin production decreases progressively and serves as the foremost reason for anemia in uremic patients. Another possibility is the shortening lifespan of red blood cells after erythropoietin therapy. In a study, Sato el al [21] found that the life span of red blood cells was lesser in hemodialysis patients than healthy controls (89 ± 28 vs. 128 ± 28 days), and life span was negatively correlated with erythropoiesis-stimulating agent (ESA) doses. Other factors such as iron deficiency, blood loss during hemodialysis, inflammation, and shortages of nutrition could also lead to anemia [22]. In this study, all patients with ESKD received ESA but none of the patients with CKD received ESA. In addition, iron profile and bone marrow iron store were not different between ESKD and CKD patients. Therefore, the greater degree of anemia in ESKD than CKD may be explained by impaired response to ESA because bone marrow hypocellularity was greater in ESKD than CKD. Further study is required to validate this finding.
The bone marrow biopsy report showed that megakaryocyte count was 3.4 ± 2.1 per high power field (Table 6). Furthermore, megakaryocyte count within bone marrow was a significant predictor for bone marrow hypocellularity (p = 0.004, Table 7). In other words, there was a 0.48 reduced risk of developing hypocellular marrow for each increase in 1 megakaryocyte per high power field. In the bone marrow, platelets are produced by megakaryocytes, which are regulated by thrombopoietin [23]. Although thrombocytopenia was described in patients with ESKD, the megakaryocyte counts in the bone marrow aspirate were not reduced [24]. The bone marrow aspiration report also showed that most of the patients had normal (71.1%) or increased (6.7%) megakaryocyte distribution (Table 5). Similarly, the number of megakaryocytes was normal or increased in the bone marrow of patients with immune thrombocytopenia [25]. The mechanisms of platelet underproduction in immune thrombocytopenia remain uncertain. Likewise, there is no clear explanation for the association between increased megakaryocyte count within bone marrow and hypocellular marrow. Further studies are warranted.
Diabetes mellitus, chronic glomerulonephritis, and hypertension accounted for 46.7%, 28.9%, and 22.2% of causes of renal insufficiency in this study (Table 2). The causes of CKD varied between different countries, ethnicities, and age. Overall, diabetes mellitus was the leading cause of CKD, which was 44% in United States, 27.5% in United Kingdom [26]. In contrast, the greatest cause of CKD in China was chronic glomerulonephritis, which was 57.4% of patients [27]. In Taiwan, the epidemiology distribution of CKD was similar to that in the United States, which was 43.2% with diabetes mellitus, 25.1% with chronic glomerulonephritis, and 8.3% with primary hypertension [28].
Patients with ESKD had higher calcium levels (p = 0.008) compared to patients with CKD. The normal kidney regulates serum calcium and phosphate level via control of intestinal absorption and renal tubular excretion. Once the regulation of the intestine and kidney are interrupted by renal impairment, the balance of serum calcium, phosphate level, parathyroid hormone, vitamin D metabolism may be disturbed. The biochemical findings of mineral bone disease included increment of fibroblast growth factor, parathyroid hormone elevation, and serum phosphate and decrement of 1,25-dihydroxyvitamin D and serum calcium [29,30,31]. With advancing kidney impairment, active vitamin D deficiency worsens and contributes to hypocalcemia and secondary hyperparathyroidism. Osteoclast activity is stimulated and finally results in abnormalities of bone turnover. Therefore, phosphate-lowering therapy and maintenance of serum calcium level are mandatory for patients of ESKD. In Taiwan, calcium-based phosphate binders are routinely used in ESKD patients because the cost is payable by National Health Insurance. Another consideration is the calcium-sensing receptor (CaSR). Several links exist between hematopoietic pathways and mineral bone metabolism, and CaSR plays an important role in the homing of hematopoietic stem cells [32]. In CaSR knockout mice, bone hypocellularity causing a reduction in hematopoietic stem cell number was observed. Defects in the adherence of CaSR deficient hematopoietic stem cells to bone marrow extracellular matrix were reported [33]. In the setting of uremia, decreased expression of CaSR was not only observed in parathyroid gland cells, but also in blood cells [34,35]. Nevertheless, the complex associations between hypercalcemia, CaSR, and bone marrow hypocellularity needs further research.
The major limitation of this retrospective observational cohort study is its small sample size. Furthermore, none of the patients received renal biopsy for confirmation of their causes of renal dysfunction. The control of anemia was not good in either group, so other factors may have influenced hemoglobin control in these patients. Nevertheless, this study is limited by lack of intact parathyroid hormone, urine protein creatinine ratio, alfa2 globulins and total protein determination. Another limitation is the lack of protocol for bone marrow biopsies and aspirations. All patients in this study received a one-off bone marrow study. None of the patients received repeated bone marrow studies for illustrating sequential pathological changes within the bone marrow. However, considering the invasiveness and complications of bone marrow procedures, protocol bone marrow biopsy and aspiration would be difficult.
5. Conclusions
With the paucity of medical literature, this study is important to elucidate bone marrow changes in patients with renal dysfunction. The analytical results show that bone marrow hypocellularity is common in patients with kidney dysfunction. Hypocellular marrow occurs more frequently in patients with ESKD than patients with CKD. Furthermore, ESKD status and megakaryocyte count within bone marrow are significant predictors of bone marrow hypocellularity.
Author Contributions
Writing—original draft preparation and data curation, C.-C.H.; writing—review and editing, M.-J.C.; Methodology, Y.-J.S.; formal analysis, J.-F.F., I.-K.W., C.-Y.C., C.-H.W., W.-H.H., C.-W.H.; Conceptualization, supervision and funding acquisition, T.-H.Y. All authors have read and agreed to the published version of the manuscript.
Funding
This research was funded by Chang Gung Memorial Hospital, grant number CORPG3K0192, CMRPG3J1053, CORPG3L0291.
Institutional Review Board Statement
This retrospective observational cohort study adhered to the guidelines of the Declaration of Helsinki and was approved by the Medical Ethics Committee of Chang Gung Memorial Hospital. The Institutional Review Board number was 202000663B0.
Informed Consent Statement
Since this study involved a retrospective review of existing data, Institutional Review Board approval was obtained without specific informed consent from the patients. However, informed consent was obtained from all patients before bone marrow biopsy. All individual information was securely protected by delinking identifying information from main data set and was only available to investigators. Furthermore, all of the data were analyzed anonymously. The Institutional Review Board of the Chang Gung Memorial Hospital had specifically waived the need for consent.
Data Availability Statement
The datasets used and analyzed in this study are available from the corresponding author upon request.
Conflicts of Interest
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
References
- Latif, R.K.; Ahmad, S.Q.; Khan, S.A.; Arshad, U.; Akhtar, Y.; Sadat, A. Spectrum of bone marrow changes in patients of chronic kidney disease (stage III, IV AND V). Pak. Armed. Forces Med. J. 2017, 67, 716–720. [Google Scholar]
- Weng, C.-H.; Lu, K.-Y.; Wen-Hung, H.; Huang, W.-H.; Wang, I.-K.; Yen, T.-H. Bone Marrow Pathology Predicts Mortality in Chronic Hemodialysis Patients. BioMed. Res. Int. 2015, 2015, 1–7. [Google Scholar] [CrossRef] [Green Version]
- Sikole, A.; Stojanovic, A.; Polenakovic, M.; Petrusevska, G.; Sadikario, S.; Saso, R.; Jovanovski, M. How Erythropoietin Affects Bone Marrow of Uremic Patients. Am. J. Nephrol. 1997, 17, 128–136. [Google Scholar] [CrossRef]
- Ho-Yen, D.O.; Saleem, N.; Fleming, L.W.; Stewart, W.K.; Goodall, H.B. Bone Marrow Cellularity and Iron Stores in Chronic Renal Failure. Acta Haematol. 1980, 64, 265–270. [Google Scholar] [CrossRef]
- Eschbach, J.W.; Adamson, J.W.; Cook, J.D. Disorders of Red Blood Cell Production in Uremia. Arch. Intern. Med. 1970, 126, 812–815. [Google Scholar] [CrossRef]
- Callen, I.R.; Limarzi, L.R. Blood and Bone Marrow Studies in Renal Disease. Am. J. Clin. Pathol. 1950, 20, 3–23. [Google Scholar] [CrossRef]
- Baltierra, D.; Harper, T.; Jones, M.P.; Nau, K.C. Hematologic Disorders: Bone Marrow Failure. FP Essent. 2015, 433, 21–26. [Google Scholar] [PubMed]
- Levey, A.S.; de Jong, P.E.; Coresh, J.; Nahas, M.E.; Astor, B.C.; Matsushita, K.; Gansevoort, R.T.; Kasiske, B.L.; Eckardt, K.-U. The definition, classification, and prognosis of chronic kidney disease: A KDIGO Controversies Conference report. Kidney Int. 2011, 80, 17–28. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, S.-H.; Erber, W.N.; Porwit, A.; Tomonaga, M.; Peterson, L.C. International Councilfor Standardization in Hematology ICSH guidelines for the standardization of bone marrow specimens and reports. Int. J. Lab. Hematol. 2008, 30, 349–364. [Google Scholar] [CrossRef] [PubMed]
- Gruppo, R.A.; Lampkin, B.C.; Granger, S. Bone marrow cellularity determination: Comparison of the biopsy, aspirate, and buffy coat. Blood 1977, 49, 29–31. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hung, S.-C.; Tarng, D.-C. Bone Marrow Iron in CKD: Correlation with Functional Iron Deficiency. Am. J. Kidney Dis. 2010, 55, 617–621. [Google Scholar] [CrossRef]
- Hamza, E.; Metzinger, L.; Meuth, V.M.-L. Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review. Cells 2020, 9, 2039. [Google Scholar] [CrossRef] [PubMed]
- Freedman, M.H.; Cattrarn, D.C.; Saunders, F. Anemia of Chronic Renal Failure: Inhibition of Erythropoiesis by Uremic Serum. Nephron 1983, 35, 15–19. [Google Scholar] [CrossRef] [PubMed]
- Chiang, C.-K.; Tanaka, T.; Inagi, R.; Fujita, T.; Nangaku, M. Indoxyl sulfate, a representative uremic toxin, suppresses erythropoietin production in a HIF-dependent manner. Lab. Investig. 2011, 91, 1564–1571. [Google Scholar] [CrossRef] [Green Version]
- Ahmed, M.S.E.; Abed, M.; Voelkl, J.; Lang, F. Triggering of suicidal erythrocyte death by uremic toxin indoxyl sulfate. BMC Nephrol. 2013, 14, 244. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dias, G.F.; Bonan, N.B.; Steiner, T.M.; Tozoni, S.S.; Rodrigues, S.; Nakao, L.S.; Kuntsevich, V.; Filho, R.P.; Kotanko, P.; Moreno-Amaral, A.N. Indoxyl Sulfate, a Uremic Toxin, Stimulates Reactive Oxygen Species Production and Erythrocyte Cell Death Supposedly by an Organic Anion Transporter 2 (OAT2) and NADPH Oxidase Activity-Dependent Pathways. Toxins 2018, 10, 280. [Google Scholar] [CrossRef] [Green Version]
- Yoshida, K.; Yoneda, T.; Kimura, S.; Fujimoto, K.; Okajima, E.; Hirao, Y. Polyamines as an Inhibitor on Erythropoiesis of Hemodialysis Patients by In Vitro Bioassay Using the Fetal Mouse Liver Assay. Ther. Apher. Dial. 2006, 10, 267–272. [Google Scholar] [CrossRef]
- Ahmed, M.S.E.; Langer, H.; Abed, M.; Voelkl, J.; Lang, F. The Uremic Toxin Acrolein Promotes Suicidal Erythrocyte Death. Kidney Blood Press. Res. 2013, 37, 158–167. [Google Scholar] [CrossRef]
- Aucella, F.; Scalzulli, R.P.; Vigilante, M.; Stallone, C. The hemodiafiltration with endogenous reinfusion reduces the erythroid progenitor inhibition by uremic serum. G. Ital. Nefrol. Organo Uff. Soc. Ital. Nefrol. 2005, 21 (Suppl. 30), S128–S132. [Google Scholar]
- Lombardero, M.; Kovacs, K.; Scheithauer, B.W. Erythropoietin: A Hormone with Multiple Functions. Pathobiology 2011, 78, 41–53. [Google Scholar] [CrossRef]
- Sato, Y.; Mizuguchi, T.; Shigenaga, S.; Yoshikawa, E.; Chujo, K.; Minakuchi, J.; Kawashima, S. Shortened Red Blood Cell Lifespan Is Related to the Dose of Erythropoiesis-Stimulating Agents Requirement in Patients on Hemodialysis. Ther. Apher. Dial. 2012, 16, 522–528. [Google Scholar] [CrossRef]
- Fishbane, S.; Spinowitz, B. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. Am. J. Kidney Dis. 2018, 71, 423–435. [Google Scholar] [CrossRef] [PubMed]
- Lambert, M.P. Platelets in liver and renal disease. Hematology 2016, 2016, 251–255. [Google Scholar] [CrossRef] [Green Version]
- Gafter, U.; Bessler, H.; Malachi, T.; Zevin, D.; Djaldetti, M.; Levi, J. Platelet Count and Thrombopoietic Activity in Patients with Chronic Renal Failure. Nephron 1987, 45, 207–210. [Google Scholar] [CrossRef] [PubMed]
- Vrbensky, J.R.; Nazy, I.; Toltl, L.J.; Ross, C.; Ivetic, N.; Smith, J.W.; Kelton, J.G.; Arnold, D.M. Megakaryocyte apoptosis in immune thrombocytopenia. Platelets 2018, 29, 729–732. [Google Scholar] [CrossRef]
- Ng, J.K.; Li, P.K.-T. Chronic kidney disease epidemic: How do we deal with it? Nephrology 2018, 23, 116–120. [Google Scholar] [CrossRef] [Green Version]
- Liu, Z.-H. Nephrology in China. Nat. Rev. Nephrol. 2013, 9, 523–528. [Google Scholar] [CrossRef] [PubMed]
- Hwang, S.-J.; Tsai, J.-C.; Chen, H.-C. Epidemiology, impact and preventive care of chronic kidney disease in Taiwan. Nephrology 2010, 15 (Suppl. S2), 3–9. [Google Scholar] [CrossRef]
- Gallant, K.M.H.; Spiegel, D.M. Calcium Balance in Chronic Kidney Disease. Curr. Osteoporos. Rep. 2017, 15, 214–221. [Google Scholar] [CrossRef] [PubMed]
- Ketteler, M.; Block, G.A.; Evenepoel, P.; Fukagawa, M.; Herzog, C.A.; McCann, L.; Moe, S.M.; Shroff, R.; Tonelli, M.A.; Toussaint, N.D.; et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: What’s changed and why it matters. Kidney Int. 2017, 92, 26–36. [Google Scholar] [CrossRef] [Green Version]
- Webster, A.C.; Nagler, E.V.; Morton, R.L.; Masson, P. Chronic Kidney Disease. Lancet 2017, 389, 1238–1252. [Google Scholar] [CrossRef]
- Drueke, T.B. Haematopoietic stem cells--role of calcium-sensing receptor in bone marrow homing. Nephrol. Dial. Transplant. 2006, 21, 2072–2074. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Adams, G.B.; Chabner, K.T.; Alley, I.R.; Olson, D.P.; Szczepiorkowski, Z.M.; Poznansky, M.C.; Kos, C.H.; Pollak, M.R.; Brown, E.M.; Scadden, D.T. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nat. Cell Biol. 2005, 439, 599–603. [Google Scholar] [CrossRef] [PubMed]
- Alfadda, T.I.; Saleh, A.M.A.; Houillier, P.; Geibel, J.P. Calcium-sensing receptor 20 years later. Am. J. Physiol. Physiol. 2014, 307, C221–C231. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mary, A.; Objois, T.; Brazier, M.; Bennis, Y.; Boudot, C.; Lenglet, G.; Paccou, J.; Bugnicourt, J.-M.; Choukroun, G.; Drueke, T.B.; et al. Decreased monocyte calcium sensing receptor expression in patients with chronic kidney disease is associated with impaired monocyte ability to reduce vascular calcification. Kidney Int. 2021, 99, 1382–1391. [Google Scholar] [CrossRef] [PubMed]
Table 1.
Published literature on bone marrow pathology in patients with kidney dysfunction.
| Study | Year | Area | Sample Size | Patient Population | Hypocellular Marrow (%) |
|---|---|---|---|---|---|
| Current study | 2021 | Taiwan | 45 | ESKD, CKD | 72.7 (ESKD), 39.1 (CKD) |
| Latif et al. [1] | 2017 | Pakistan | 57 | CKD | 1.75 |
| Weng et al. [2] | 2015 | Taiwan | 78 | ESKD | 51.3 |
| Sikole et al. [3] | 1997 | North Macedonia | 32 | ESKD | 60 |
| Ho-Yen et al. [4] | 1980 | Scotland | 30 | CKD | No hypocellular marrow |
| Eschbach et al. [5] | 1970 | United States | 90 | CKD | 53.3 |
| Callen et al. [6] | 1950 | United States | 102 | CKD | 80% hypercelluarity |
Note: CKD chronic kidney disease, ESKD end-stage kidney disease.
Table 2.
Indications for bone marrow examination, stratified by renal function as ESKD or CKD (n = 45).
Table 2.
Indications for bone marrow examination, stratified by renal function as ESKD or CKD (n = 45).
| Indications for Bone Marrow Examination | All Patients (n = 45) | Patients with ESKD (n = 22) | Patients with CKD (n = 23) | p Value |
|---|---|---|---|---|
| 0.146 | ||||
| Unexplained anemia, n (%) | 40 (88.9) | 18 (81.8) | 22 (95.7) | |
| Pancytopenia, n (%) | 3 (6.7) | 3 (13.6) | 0 (0) | |
| Thrombocytopenia, n (%) | 1 (2.2) | 1 (2.2) | 0 (0) | |
| Fever of unknown origin, n (%) | 1 (2.2) | 0 (0) | 1 (4.3) |
Table 3.
Baseline characteristics of patients, stratified by renal function as ESKD or CKD (n = 45).
Table 3.
Baseline characteristics of patients, stratified by renal function as ESKD or CKD (n = 45).
| Variable | All Patients (n = 45) | Patients with ESKD (n = 22) | Patients with CKD (n = 23) | p Value |
|---|---|---|---|---|
| Demographics | ||||
| Age (year) [range] | 57.0 ± 16.4 [17.0–81.0] | 52.1 ± 18.6 [17.0–80.0] | 61.7 ± 12.6 [39.0–81.0] | 0.047 * |
| Male, n (%) | 22 (48.9) | 13 (59.1) | 9 (39.1) | 0.181 |
| Body mass index (kg/m2) | 23.4 ± 4.9 | 23.6 ± 3.7 | 23.2 ± 5.8 | 0.796 |
| Hypertension, n (%) | 41 (91.1) | 21 (95.5) | 20 (87.0) | 0.317 |
| Coronary artery disease, n (%) | 7 (15.6) | 3 (13.6) | 4 (17.4) | 0.728 |
| Alcohol consumption, n (%) | 2 (4.4) | 1 (4.5) | 1 (4.3) | 0.974 |
| Smoking habit, n (%) | 2 (4.4) | 1 (4.5) | 1 (4.3) | 0.974 |
| Betel nut chewing, n (%) | 1 (2.2) | 1 (4.5) | 0 (0) | 0.301 |
| Causes of kidney dysfunction, n (%) | 0.686 | |||
| Diabetes mellitus | 21 (46.7) | 9 (40.9) | 12 (52.2) | |
| Hypertension | 10 (22.2) | 5 (22.7) | 5 (21.7) | |
| Glomerulonephritis | 13 (28.9) | 7 (31.8) | 6 (26.1) | |
| Unknown | 1 (2.2) | 1 (4.5) | 0 (0) | |
| Stage of CKD, n (%) | <0.001 * | |||
| Stage 3 | 2 (4.4) | 0 (0) | 2 (8.7) | |
| Stage 4 | 10 (22.2) | 0 (0) | 10 (43.5) | |
| Stage 5 | 33 (73.3) | 22 (100) | 11 (47.8) |
Note: * p < 0.05.
Table 4.
Laboratory findings of patients, stratified by renal function as ESKD or CKD (n = 45).
| Variable | All Patients (n = 45) | Patients with ESKD (n = 22) | Patients with CKD (n = 23) | p Value |
|---|---|---|---|---|
| Estimated glomerular filtration rate (cc/min) | 11.0 ± 11.0 | 4.7 ± 1.5 | 16.9 ± 12.9 | <0.001 *** |
| Blood urea nitrogen (mg/dL) | 74.0 ± 31.2 | 83.4 ± 30.2 | 63.1 ± 29.5 | 0.041 * |
| Creatinine (mg/dL) | 7.7 ± 4.5 | 11.4 ± 3.1 | 4.1 ± 2.0 | <0.001 *** |
| Alanine aminotransferase (U/L) | 29.0 ± 29.2 | 33.5 ± 31.0 | 23.4 ± 26.6 | 0.296 |
| Calcium (mg/dL) | 9.0 ± 1.3 | 9.4 ± 1.3 | 8.2 ± 0.8 | 0.008 * |
| Phosphorus (mEq/L) | 5.5 ± 1.6 | 5.8 ± 1.5 | 5.0 ± 1.7 | 0.169 |
| Sodium (mEq/L) | 137.4 ± 4.0 | 136.4 ± 4.4 | 139.5 ± 1.8 | 0.043 * |
| Potassium (mEq/L) | 4.4 ± 0.7 | 4.2 ± 0.6 | 4.6 ± 0.6 | 0.054 |
| Albumin (g/dL) | 3.6 ± 0.4 | 3.7 ± 0.5 | 3.5 ± 0.3 | 0.290 |
| Glycated hemoglobin (%) | 5.8 ± 1.0 | 5.7 ± 0.7 | 6.0 ± 1.4 | 0.429 |
| High density lipoprotein (mg/dL) | 41.6± 12.2 | 39.5 ± 11.3 | 44.8 ± 13.3 | 0.251 |
| Low density lipoprotein (mg/dL) | 119.9 ± 90.0 | 120.1 ± 89.4 | 119.7 ± 94.2 | 0.992 |
| Total cholesterol (mg/dL) | 176.81 ± 73.22 | 173.45 ± 73.39 | 181.0 ± 75.20 | 0.763 |
| Triglyceride (mg/dL) | 169.6 ± 275.4 | 137.7 ± 111.3 | 212.1 ± 404.9 | 0.437 |
| Iron (μg/dL) | 84.3 ± 54.0 | 86.8 ± 59.2 | 78.1 ± 41.6 | 0.709 |
| Total iron binding capacity (μg/dL) | 259.1 ± 58.0 | 267.0 ± 55.0 | 241.3 ± 64.3 | 0.306 |
| Iron/Total iron binding capacity (μg/dL) | 0.3 ± 0.2 | 0.3 ± 0.2 | 0.4 ± 0.2 | 0.807 |
| Ferritin (ng/mL) | 996.5 ± 963.3 | 1038.9 ± 881.0 | 919.4 ± 1139.8 | 0.747 |
| White blood cells (103/uL) | 5.8 ± 2.7 | 5.8 ± 3.1 | 5.8 ± 2.4 | 0.965 |
| Red blood cell (106/uL) | 2.6 ± 0.6 | 2.5 ± 0.4 | 2.8 ± 0.6 | 0.046 * |
| Hemoglobin (g/dL) | 7.9 ± 1.6 | 7.3 ± 1.3 | 8.4 ± 1.6 | 0.017 * |
| Hematocrit (%) | 23.4 ± 4.6 | 21.9 ± 3.9 | 25.0 ± 4.9 | 0.025 * |
| Mean corpuscular volume (fL) | 90.1 ± 9.8 | 89.1 ± 10.2 | 91.1 ± 9.6 | 0.517 |
| Mean corpuscular hemoglobin (pg/cell) | 30.1 ± 3.6 | 29.9 ± 3.8 | 30.3 ± 3.4 | 0.765 |
| Mean corpuscular hemoglobin concentration (g/dL) | 33.6 ± 1.2 | 33.6 ± 1.2 | 33.6 ± 1.3 | 0.983 |
| Red blood cell distribution width (%) | 15.7 ± 3.7 | 16.6 ± 4.0 | 14.8 ± 3.1 | 0.121 |
| Platelet (103/uL) | 157.5 ± 87.2 | 153.9 ± 89.0 | 161.1 ± 87.3 | 0.787 |
| Neutrophil (%) | 67.9 ± 12.7 | 66.4 ± 13.5 | 69.2 ± 12.1 | 0.519 |
| Lymphocyte (%) | 19.5 ± 8.3 | 17.6 ± 7.9 | 21.2 ± 8.4 | 0.198 |
| Monocyte (%) | 7.4 ± 4.3 | 8.2 ± 4.5 | 6.7 ± 4.1 | 0.283 |
| Eosinophil (%) | 3.1 ± 3.3 | 2.7 ± 2.1 | 3.4 ± 4.2 | 0.540 |
| Basophil (%) | 0.4 ± 0.6 | 0.3 ± 0.4 | 0.5 ± 0.7 | 0.313 |
Note: * p < 0.05, *** p < 0.001.
Table 5.
Reports of bone marrow aspiration (n = 45).
| Variable | All Patients (n = 45) | Patients with ESKD (n = 22) | Patients with CKD (n = 23) | p Value |
|---|---|---|---|---|
| Cellularity | 0.011 * | |||
| Hypercellularity or normocellularity, n (%) | 23 (51.1) | 7 (31.8) | 16 (69.6) | |
| Hypocellularity, n (%) | 22 (48.9) | 15 (68.2) | 7 (30.4) | |
| Megakaryocyte distribution | 0.107 | |||
| Absent, n (%) | 1 (2.2) | 1 (4.5) | 0 (0) | |
| Decreased, n (%) | 9 (20.0) | 7 (31.8) | 2 (8.7) | |
| Normal, n (%) | 32 (71.1) | 12 (54.5) | 20 (87.0) | |
| Increase, n (%) | 3 (6.7) | 2 (9.1) | 1 (4.3) | |
| Morphology, megakaryocytes | 0.201 | |||
| Normal, n (%) | 43 (95.6) | 20 (90.9) | 23 (100) | |
| Dysplasia, n (%) | 1 (2.2) | 1 (4.5) | 0 (0) | |
| Absent, n (%) | 1 (2.2) | 1 (4.5) | 0 (0) | |
| Myeloid/erythroid ratio | 2.1 ± 1.4 | 2.3 ± 1.8 | 1.8 ± 0.8 | 0.285 |
| Myeloid series, n (%) | 49.6 ± 14.3 | 50.7 ± 15.2 | 48.6 ± 13.7 | 0.627 |
| Blast, n (%) | 0.8 ± 0.9 | 0.5 ± 0.8 | 1.1 ± 0.8 | 0.033 * |
| Promyelocyte, n (%) | 1.7 ± 1.8 | 1.8 ± 2.0 | 1.6 ± 1.7 | 0.717 |
| Myelocyte and metamyelocyte, n (%) | 16.4 ± 6.6 | 17.7 ± 7.4 | 15.3 ± 5.5 | 0.226 |
| Band and segmental cell, n (%) | 31.2 ± 12.3 | 30.8 ± 12.2 | 30.7 ± 11.9 | 0.980 |
| Morphology of myeloid series | 0.139 | |||
| Normal | 43 (95.6) | 20 (90.9) | 23 (100) | |
| Abnormal | 2 (4.4) | 2 (9.1) | 0 (0) | |
| Erythroid series (%) | 30.4 ± 13.3 | 32.0 ± 16.6 | 28.8 ± 9.3 | 0.424 |
| Morphology of erythroid series | 0.139 | |||
| Normal | 43 (95.6) | 20 (90.9) | 23 (100) | |
| Abnormal | 2 (4.4) | 2 (9.1) | 0 (0) | |
| Monohistiocyte (%) | 0.9 ± 0.9 | 1.1 ± 1.2 | 0.8 ± 0.7 | 0.307 |
| Eosinophil (%) | 2.8 ± 1.8 | 2.4 ± 1.7 | 3.2 ± 1.8 | 0.132 |
| Plasma cell (%) | 1.8 ± 2.4 | 1.3 ± 1.6 | 2.3 ± 2.8 | 0.151 |
| Lymphoid cell (%) | 13.0 ± 6.9 | 13.0 ± 8.1 | 13.0 ± 5.5 | 0.969 |
| Sideroblast, grade, n (%) | 0.462 | |||
| Normal | 5 (11.4) | 2 (9.5) | 3 (13.0) | |
| Increase | 19 (43.2) | 7 (33.3) | 12 (52.2) | |
| Decrease | 6 (13.6) | 3 (14.3) | 3 (13.0) | |
| Absent | 14 (31.8) | 9 (42.9) | 5 (21.7) | |
| Iron staining, grade, n (%) | 0.086 | |||
| Grade 0 | 7 (15.9) | 2 (9.5) | 5 (21.7) | |
| Grade 1 | 2 (4.5) | 1 (4.8) | 1 (4.3) | |
| Grade 2 | 3 (6.8) | 0 (0) | 3 (13.0) | |
| Grade 3 | 19 (43.2) | 14 (66.7) | 5 (21.7) | |
| Grade 4 | 10 (22.7) | 3 (14.3) | 7 (30.4) | |
| Grade 5 | 2 (4.5) | 1 (4.8) | 1 (4.3) | |
| Grade 6 | 1 (2.3) | 0 (0) | 1 (4.3) |
Note: * p < 0.05.
Table 6.
Reports of bone marrow biopsy (n = 45).
| Variable | All Patients (n = 45) | Patients with ESKD (n = 22) | Patients with CKD (n = 23) | p Value |
|---|---|---|---|---|
| Cellularity | 0.023 * | |||
| Hypercellularity or normocellularity, n (%) | 20 (44.4) | 6 (27.3) | 14 (60.9) | |
| Hypocellularity, n (%) | 25 (55.6) | 16 (72.7) | 9 (39.1) | |
| Myeloid/erythroid ratio | 2.2 ± 1.2 | 2.3 ± 1.5 | 2.1 ± 1.0 | 0.626 |
| Megakaryocyte, per high power field | 3.4 ± 2.1 | 3.5 ± 2.0 | 3.4 ± 2.2 | 0.867 |
| Reticulin staining, grade | ||||
| Grade 0 | 42 (93.3) | 20 (90.9) | 22 (95.7) | 0.524 |
| Grade 1 | 3 (6.7) | 2 (9.1) | 1 (4.3) | |
| Iron staining, grade, n (%) | 0.297 | |||
| Grade 0 | 8 (17.8) | 4 (18.2) | 4 (17.4) | |
| Grade 1 | 3 (6.7) | 2 (9.1) | 1 (4.3) | |
| Grade 2 | 24 (53.3) | 9 (40.9) | 15 (65.2) | |
| Grade 3 | 7 (15.6) | 5 (22.7) | 2 (8.7) | |
| Grade 4 | 2 (4.4) | 2 (9.1) | 0 (0) | |
| Grade 5 | 1 (2.2) | 0 (0) | 1 (4.3) | |
| Grade 6 | 0 (0) | 0 (0) | 0 (0) |
Note: * p < 0.05.
Table 7.
Analysis of predictors for bone marrow hypocellularity (n = 45).
| Variable | Univariate Logistic Regression Analysis | Multivariate Logistic Regression Analysis | ||||
|---|---|---|---|---|---|---|
| Odds Ratio | 95% Confidence Interval | p Value | Odds Ratio | 95% Confidence Interval | p Value | |
| ESKD status (yes) | 4.149 | 1.179–14.493 | 0.027 * | 9.43 | 1.66–53.63 | 0.011 * |
| Age (per 1 year increase) | 0.98 | 0.94–1.02 | 0.233 | |||
| Sex (male) | 1.32 | 0.41–4.31 | 0.641 | |||
| BMI (per 1 kg/m2 increase) | 0.91 | 0.79–1.06 | 0.222 | |||
| Coronary artery disease (yes) | 0.93 | 0.18–4.72 | 0.927 | |||
| Hypertension (yes) | 0.78 | 0.10–6.10 | 0.815 | |||
| Alcohol consumption (yes) | 1.26 | 0.07–21.74 | 0.872 | |||
| Betel nut chewing (yes) | 1.26 | 0.07–21.74 | 0.872 | |||
| Estimated glomerular filtration rate (per 1 cc/min increase) | 0.98 | 0.93–1.04 | 0.589 | |||
| Blood urea nitrogen (per 1 mg/dL increase) | 1.02 | 0.99–1.04 | 0.147 | |||
| Creatinine (per 1 mg/dL increase) | 1.14 | 0.98–1.32 | 0.085 | |||
| Alanine aminotransferase (per 1 U/L increase) | 1.03 | 0.99–1.07 | 0.138 | |||
| Calcium (per 1 mg/dL increase) | 1.12 | 0.64–1.96 | 0.701 | |||
| Phosphorus (per 1 mEq/L increase) | 1.33 | 0.82–2.18 | 0.251 | |||
| Sodium (per 1 mEq/L increase) | 1.06 | 0.88–1.26 | 0.533 | |||
| Potassium (per 1 mEq/L increase) | 1.02 | 0.38–2.75 | 0.966 | |||
| Albumin (per 1 g/dL increase) | 3.08 | 0.52–18.18 | 0.217 | |||
| Glycated hemoglobin (per 1% increase) | 0.73 | 0.30–1.74 | 0.472 | |||
| High density lipoprotein (per 1 mg/dL increase) | 1.00 | 0.94–1.06 | 0.886 | |||
| Low density lipoprotein (per 1 mg/dL increase) | 0.995 | 0.986–1.004 | 0.265 | |||
| Total cholesterol (per 1 mg/dL increase) | 0.99 | 0.98–1.00 | 0.147 | |||
| Triglyceride (per 1 mg/dL increase) | 1.00 | 0.991–1.004 | 0.378 | |||
| Iron (per 1 μg/dL increase) | 1.01 | 0.99–1.02 | 0.354 | |||
| Total iron binding capacity (per 1 μg/dL increase) | 1.00 | 0.98–1.01 | 0.725 | |||
| Iron/Total iron binding capacity (per 1 μg/dL increase) | 1.00 | 0.99–1.01 | 0.548 | |||
| Ferritin (per 1 ng/mL increase) | 1.001 | 1.000–1.002 | 0.138 | |||
| White blood cells (per 103/uL increase) | 0.79 | 0.62–1.02 | 0.067 | |||
| Red blood cell (per 1 × 106 /uL increase) | 0.29 | 0.07–1.15 | 0.078 | |||
| Hemoglobin (per 1 g/dL increase) | 0.70 | 0.45–1.09 | 0.115 | |||
| Hematocrit (%) (per 1% increase) | 0.91 | 0.80–1.05 | 0.189 | |||
| Mean corpuscular volume (per 1 fL increase) | 1.03 | 0.97–1.10 | 0.322 | |||
| Mean corpuscular hemoglobin (per 1 pg/cell increase) | 1.06 | 0.89–1.26 | 0.516 | |||
| Mean corpuscular hemoglobin concentration (per 1 g/dL increase) | 0.73 | 0.44–1.25 | 0.262 | |||
| Red blood cell distribution width (per 1% increase) | 1.02 | 0.86–1.20 | 0.858 | |||
| Platelet (per 1 × 103 /uL increase) | 0.994 | 0.987–1.001 | 0.106 | |||
| Neutrophil (per 1% increase) | 0.95 | 0.90–1.01 | 0.099 | |||
| Lymphocyte (per 1% increase) | 1.00 | 0.93–1.09 | 0.888 | |||
| Monocyte (per 1% increase) | 0.92 | 0.92–1.28 | 0.316 | |||
| Eosinophil (per 1% increase) | 0.96 | 0.79–1.18 | 0.715 | |||
| Basophil (per 1% increase) | 1.06 | 0.33–3.37 | 0.924 | |||
| Bone marrow aspiration | ||||||
| Myeloid/erythroid ratio (per of 1 increase) | 1.09 | 0.70–1.68 | 0.708 | |||
| Myeloid series (per 1% increase) | 0.99 | 0.95–1.04 | 0.752 | |||
| Blast (per 1% increase) | 0.86 | 0.43–1.73 | 0.571 | |||
| Promyelocyte (per 1% increase) | 1.07 | 0.76–1.51 | 0.685 | |||
| Myelocyte and metamyelocyte (per 1% increase) | 0.97 | 0.89–1.07 | 0.550 | |||
| Band and segmental cell (per 1% increase) | 1.00 | 0.95–1.05 | 0.972 | |||
| Morphology of myeloid series (normal) | 1.26 | 0.07–21.74 | 0.872 | |||
| Erythroid series (per 1% increase) | 0.99 | 0.95–1.04 | 0.745 | |||
| Morphology of erythroid series (normal) | 1.31 | 0.07–21.74 | 0.872 | |||
| Monohistiocyte (per 1% increase) | 1.82 | 0.75–4.41 | 0.183 | |||
| Eosinophil (per 1% increase) | 1.00 | 0.71–1.41 | 0.986 | |||
| Plasma cell (per 1% increase) | 0.88 | 0.66–1.17 | 0.374 | |||
| Lymphoid cell (per 1% increase) | 1.00 | 0.91–1.09 | 0.908 | |||
| Iron staining (per 1 grade increase) | 1.23 | 0.82–1.85 | 0.316 | |||
| Bone marrow biopsy | ||||||
| Myeloid/erythroid ratio (per 1 increase) | 0.96 | 0.59–1.58 | 0.878 | |||
| Megakaryocyte (per 1 cell high power field increase) | 0.59 | 0.40–0.86 | 0.005 ** | 0.48 | 0.29–0.79 | 0.004 ** |
| Reticulin staining (per 1 grade increase) | 2.67 | 0.22–32.26 | 0.438 | |||
| Iron staining (per 1 grade increase) | 1.25 | 0.84–1.84 | 0.268 | |||
Note: * p < 0.05, ** p < 0.01.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Hsieh, C.-C.; Chan, M.-J.; Su, Y.-J.; Fu, J.-F.; Wang, I.-K.; Chen, C.-Y.; Weng, C.-H.; Huang, W.-H.; Hsu, C.-W.; Yen, T.-H. Bone Marrow Hypocellularity in Patients with End-Stage Kidney Disease. Healthcare 2021, 9, 1452. https://doi.org/10.3390/healthcare9111452
AMA Style
Hsieh C-C, Chan M-J, Su Y-J, Fu J-F, Wang I-K, Chen C-Y, Weng C-H, Huang W-H, Hsu C-W, Yen T-H. Bone Marrow Hypocellularity in Patients with End-Stage Kidney Disease. Healthcare. 2021; 9(11):1452. https://doi.org/10.3390/healthcare9111452
Chicago/Turabian StyleHsieh, Chia-Chen, Ming-Jen Chan, Yi-Jiun Su, Jen-Fen Fu, I-Kuan Wang, Chao-Yu Chen, Cheng-Hao Weng, Wen-Hung Huang, Ching-Wei Hsu, and Tzung-Hai Yen. 2021. "Bone Marrow Hypocellularity in Patients with End-Stage Kidney Disease" Healthcare 9, no. 11: 1452. https://doi.org/10.3390/healthcare9111452
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
